Chirality and drugs used in psychiatry: Nice to know or need to know?

Cellular and Molecular Neurobiology

Volumn 19, Issue 3, 1999, Pages 355-372

  Lane, Roger M ^a   Baker, Glen B ^b  

^a PFIZER INC   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Chiral; Cytochrome P450; Enantiomers; Geometric isomers; Pharmacokinetics; Racemic; Stereoselective

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CLORGYLINE; CYTOCHROME P450; DOXEPIN; ENZYME; EPHEDRINE; FLUOXETINE; FLUVOXAMINE; LEVOMEPROMAZINE; MIANSERIN; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; PHENOTHIAZINE DERIVATIVE; PSEUDOEPHEDRINE; RECEPTOR; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THIORIDAZINE; THIOXANTHENE DERIVATIVE; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; VILOXAZINE; ZOPICLONE;

ARTICLE; CHIRALITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; ENANTIOMER; GENETIC POLYMORPHISM; HUMAN; NONHUMAN; PRIORITY JOURNAL; RACEMIC MIXTURE; STEREOCHEMISTRY;

DRUG THERAPY; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; PSYCHIATRY; PSYCHOTROPIC DRUGS; STEREOISOMERISM;

EID: 0032915925     PISSN: 02724340     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006997731966     Document Type: Article

References (134)

1. Alebic-Kolbah, T., Kajfez, F., Rendic, S., Sunjic, V., Konowal, A., and Snatzke, G. (1979). Circular dichroism and gel filtration study of binding of prochiral and chiral 1,4-benzodiazepine 2-ones to human serum albumin. Biochem. Pharmacol. 28:2457-2464.
2. 3H] 5-hydroxytryptamine binding to multiple sites (5-HT1A, 5HT1B and 5-HT1C) by mianserin and propranolol. J. Pharm. Pharmacol. 39:664-666.
3. Ariens, E. J. (1984). Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology. Eur. J. Clin. Pharmacol. 26: 663-668.
4. Aspeslet, L. J., Baker, G. B., Coutts, R. T., and Torok-Both, G. A. (1994). The effects of desipramine and iprindole on levels of enantiomers of fluoxetine in rat brain and urine. Chirality 6:86-90.
5. Baier-Weber, B., Prox, A., Wachsmuth, H., and Breyer-Pfaff, U. (1988). Glucuronides of hydroxylated metabolites of amitriptyline and nortriptyline isolated from rat bile. Drug Metab. Dispos. 16:490-496.
6. Baumann, P. (1992). Clinical pharmacokinetics of citalopram and other selective serotogenic reuptake inhibitors (SSRI). Int. Clin. Psychopharmacol. 6:13-20
7. Baumann, P., and Rochat, B. (1995). Comparative pharmacokinetics of selective serotonin reuptake inhibitors: A look behind the mirror. Int. Clin. Psychopharmacol. 10:15-21.
8. 45calcium uptake in synaptosomes from the cortex of the rat brain. Neuropharmacology 31:229-234.
9. Benfield, P., and Ward, A. (1986). Fluvoxamine: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in depressive illness. Drugs 32:313-334.
10. Bertilsson, L., and Alexanderson, B. (1972). Stereospecific hydroxylation of nortriptyline in man in relationship to interindividual differences in its steady-state plasma level. Eur. J. Clin. Pharmacol. 4:201-205.
11. Bertilsson, L., Mellstrom, B., and Sjöqvist, F. (1979). Pronounced inhibition of noradrenaline uptake bylO-hydroxy-metabolites of nortriptyline. Life Sci. 25:1285-1292.
12. Blaschke, G., Hempel, G., and Muller, W. E. (1993). Preparation and analytical separation of the zopiclone enantiomers and determination of their affinity to the benzodiazepine receptor binding site. Chirality 5:419-421.
13. Boireau, A., Blanchard, J.-C., Garret, C., and Julou, L. (1980). The use of thioproperazine, a phenothiazine derivative, as a ligand for neuroleptic receptors. II. In vivo studies. Biochem. Pharmacol. 29:2339.
14. Bowman, W. C., and Rand, M. J. (1980). Textbook of Pharmacology, 2nd ed., Blackwell Scientific, Oxford, pp. 15-16.
15. Brosen, K. (1990). Recent developments in hepatic drug oxidation (implications for clinical pharmacokinetics). Clin. Pharmacokinet. 18:220-239
16. Cahn, R. S., Ingold, C. K., and Prelog, V. (1966). The specification of asymmetric configuration in organic chemistry. Experientia 12:81-124.
17. Caldwell, J. (1992). The importance of stereochemistry in drug action and disposition. J. Clin. Pharmacol. 32:925-929.
18. Caldwell, J. (1996). Importance of stereospecific bioanalytical monitoring in drug development. J. Chromatogr. A 719:3-13.
19. Campbell, D. B. (1990). Selectivity in clinical pharmacokinetics and drug development. Eur. J. Drug Metab. Pharmacokinet. 15:109-125.
20. Camilleri, P., de Baisi, V., and Hutt, A. (1994). Resolving the problem. Chem. Brit. 30:43-46.
21. Case, D. E., and Reeves, P. R. (1975). The disposition and metabolism of viloxazine in humans. Xenobiotica 5:113-129.
22. Cheeta, S., Broekkamp, C., and Winner, P. (1994). Stereospecific reversal of stress-induced anhedonia by mianserin and its (+)-enantiomer. Psychopharmacology 116:523-528.
23. Corbella, A., Gariboldi, P., Jommi, A., Forgione, A., Marcucci, F., Martelli, E., Mussani, E., and Mauri, F. (1973). Stereochemistry of the enzymic 3-hydroxylation of 1,3-dihydro-2H-1,4-benzodiazepine-2-ones. J. Chem. Soc. Chem. Commun. 721-722.
24. Coutts, R. T., and Baker, G.B. (1989). Implications of chirality and geometric isomerism in some psychoactive drugs and their metabolites. Chirality 99-120.
25. Dahl, M. L., Tybring, G., Elwin, C. E., Andreasson, K., Gyllenpalm, M., and Bertilsson, L. (1994). Stereoselective disposition of mianserin is related to debrisoquine hydroxylation. Clin. Pharmacol. Ther. 56:176-183.
26. Drayer, D. E. (1988). Problems in therapeutic drug monitoring: the dilemma of enantiomeric drugs in man. Ther. Drug Monit. 10:1-7.
27. Drayer, D. E. (1986). Pharmacodynamic and pharmacokinetic differences between drug enantiomers in humans: An overview. Clin. Pharmacol. Ther. 40:125-133.
28. Ducharme, J., Fernandez, C., Gimenez, F., and Farinotti, R. (1996). Critical issues in chiral drug analysis in biological fluids by high-performance liquid chromatography. J. Chromatogr. B Biomed. Appl. 686:65-75.
29. Dumont, E., Von Bahr, C., Perry, T. L., and Bertilsson, L. (1987). Glucuronidation of the enantiomers of E-10-hydroxynortriptyline in human and rat liver microsomes. Pharmacol. Toxicol. 61:335-341.
30. Eap, C. B., Koeb, L., Holsboer-Trachsler, E., and Baumann, P. (1992). Plasma levels of trimipramine and metabolites in four patients: Determination of the enantiomer concentrations of the hydroxy metabolites. Ther. Drug. Monit. 14:380-385.
31. Eap, C. B., Powell, K., Campussouche, D., Monney, C., Baettig, D., Taeschner, W., and Bauman, P. (1994). Determination of the enantiomers of mianserin, desmethylmianserin, and 8-hydroxymianserin in the plasma and urine of mianserin-treated patients. Chirality 6:555-563.
32. Eap, C. B., Gaillard, N., Powell, K., and Bauman, P. (1996a). Simultaneous determination of plasma levels of fluvoxamine and of the enantiomers of fluoxetine and norfluoxetine by gas chromatography-mass spectrometry. J. Chromatogr. B 682:265-272.
33. Eap, C. B., Guentert, T. W., Schaublin Loidl, M., Stabl, M., Koeb, L., Powell, K., and Baumann, P. (1996b). Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin. Clin. Pharmacol. Ther. 59:322-331.
34. Eap, C. P., Powell, K., and Baumann, P. (1997) Determination of the enantiomers of mianserin and its metabolites in plasma by capillary electrophoresis after liquid-liquid extraction and on-column sample preconcentrations. J. Chromatogr. Sci. 35:315-320.
35. Eichelbaum, M. (1992). Pharmacokinetic and pharmacodynamic consequences of stereoselective drug metabolism in man. Biochem. Pharmacol. 37:93-96.
36. Evans, A. M. (1992). Enantioselective pharmacodynamics and pharmacokinetics of chiral non-steroidal anti-inflammatory drugs. Eur. J. Clin. Pharmacol. 42:237-256.
37. Evans, A. M., Nation, R. H., Sansom, L. N., Bochner, F., and Somogyi, A. A (1988). Stereoselective drug disposition: Potential for misinterpretation of drug disposition data. Br. J. Clin. Pharmacol. 26:771-780.
38. Fassihi, A. R. (1993). Racemates and enantiomers in drug development. Int. J. Pharmacol. 92:1-14.
39. Fava, M. M., Rappe, S. M., Pava, J. A., Nierenberg, A. A., Alpert, J. E., and Rosenbaum, J. F. (1995). Relapse in patients on long-term fluoxetine treatment: Response to increased fluoxetine dose. J. Clin. Psychiatry. 56:52-55.
40. Fernandez, C., Gimenez, F., Baune, B., and Maradeix, V. (1993a). Determination of the enantiomers of zopiclone and its two chiral metabolites in urine using an automated coupled achiral chiral chromatographic system. J. Chromatogr. 617:271-278.
41. Fernandez, C., Maradeix, V., Gimenez, F., Thuillier, A., and Farinotti, R. (1993b). Pharmacokinetics of zopiclone and its enantiomers in caucasian young healthy volunteers. Drug Metab. Dispos. 21:1125-1128.
42. 11C-labeled suicide inactivators and PET. Science 235:481-485.
43. Fuentes, J. A., Oleshansky, M. A., and Neff, N. H (1976). Comparison of the apparent antidepressant activity of (+)- and (-)-tranylcypromine in an animal model. Biochem. Pharmacol. 25:801-804.
44. Fuller, R. W., Snoddy, H. D., Krushinski, J. H., and Robertson, D. W. (1992). Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors in vivo. Neuropsychopharmacology 31:997-1000.
45. Gerlach, M., Youdim, M. B. H., and Riederer, P. (1996). Pharmacology of selegiline. Neurology 47 (Suppl. 3):S137-S145.
46. Gibaldi, M. (1993). Stereoselective and isozyme-selective drug interactions. Chirality 5:407-413.
47. Goodnick, P. J. (1991). Pharmacokinetics of second generation antidepressants: Bupropion. Psychopharmacol. Bull. 27:513-519.
48. 2 and beta-adrenergic receptor regulation in rat brain following chronic treatment with desipramine and fluoxetine alone and in combination. J. Neurochem. 62:2262-2268.
49. Görög, S., and Gazdag, M. (1994). Enantiomeric derivatization for biomedical chromatography. J. Chromatogr. 659:51-84.
50. Grace, J. M., Kinter, M. T., and Macdonald, T. L. (1994). Atypical metabolism of deprenyl and its enantiomer, (S)-(+)-N,α-dimethyl-N-propynylphenethylamine, by cytochrome P450 2D6. Chem. Res. Toxicol. 7:286-290.
51. Gram, L. F. (1994). Fluoxetine. N. Engl. J. Med. 331:1354-61.
52. Gross, G., Xin, X., and Gastpar, M. (1991). Trimipramine: Pharmacological reevaluation and comparison with clozapine. Neuropharmacology 30:1159-1166.
53. Hampson, D. R., Baker, G. B., and Coutts, R. T. (1986). A comparison of the neurochemical properties of the stereoisomers of tranylcypromine in the central nervous system. Cell. Mol. Biol. 32:593-599.
54. Hand, T. H., Marek, G. J., and Seiden, L. S. (1991). Comparison of the effects of mianserin and its enantiomers and metabolites on a behavioral screen for antidepressant activity. Psychopharmacology 105:453-458.
55. Haupt, D. (1997) Determination of citalopram enantiomers in human plasma by liquid Chromatographie separation on a chiral-AGP column. J. Chromatogr. B Biomed. Appl. 685:299-305.
56. Heinig, R., and Blaschke, G. (1993). In vivo and in vitro stereoselective metabolism of mianserin in mice. Arzneimittelforschung 43:5-10.
57. Heinig, R., Delbressine, L. P., Kaspersen, F. M., and Blaschke, G. (1993). Enantiomeric aspects of the metabolism of mianserin in rats. Arzneimittelforschung 43:709-715.
58. Hempel, G., and Blaschke, G. (1996). Enantioselective determination of zopiclone and its metabolites in urine by capillary electrophoresis. J. Chromatogr. B Bio Med Appl. 675:139-146.
59. Hobbs, D. C. (1969). Distribution and metabolism of doxepine. Biochem. Pharmacol. 18:1941-1954.
60. Horn, A. S., and Snyder, S. H. (1972). Steric requirements for catecholamine uptake by rat brain synaptosomes: Studies with rigid analogs of amphetamine. J. Pharmacol. Exp. Ther. 180:523-530.
61. Hrdina, P. D., Bakish, D., Swenson, S., and Lapierre Y. D. (1990). Cis- and trans-isomers of deoxepin and desmethyldoxepin in the plasma of depressed patients treated with doxepin. Ther. Drug Monit. 12:129-133.
62. Hutt, A. J., and Tan, S. C. (1996). Drug chirality and its clinical significance. Drugs 52:1-12.
63. Hutt, A. J., Hadley, M. R., and Tan, S. C. (1994). Enantiospecific analysis: Applications in bioanalysis and metabolism. Eur. J. Drug Metab. Pharmacokin. 19:241-251.
64. Hyttel, J., Bogeso, K. P., Perregaard, J., and Sanchez, C. (1992). The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. J. Neural. Transm. 88:157-160.
65. Jamali, F., Mahvar, R., and Pasutto, F. M. (1989). Enantioselective aspects of drug action and disposition: therapeutic pitfalls. J. Pharm. Sci. 78:695-715.
66. Jancsar, S. M., and Leonard, B. E. (1984). The effect of (+/-)mianserin and its enantiomers on the behavioural hyperactivity of the olfactory-bulbectomized rat. Neuropharmacology 23:1065-1070.
67. Jortani, S. A., and Poklis, A. (1993). Determination of thioridazine enantiomers in human serum by sequential achiral and chiral high-performance liquid chromatography. J. Anal. Toxicol. 17:374-377.
68. Kaiser, C., and Setler, P. E. (1981). Antipsychotic agents. In Wolff, M. E. (ed.), Burger's Medicinal Chemistry, Part 111, 4th ed., John Wiley and Sons, New York, p. 859.
69. 3 receptors in cultured mouse neuroblastoma cells. Neuropharmacology 33:501-507.
70. Koyama, E., Chiba, K., Tani, M., and Ishizaki, T. (1996). Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. J. Pharmacol. Exp. Ther. 278:21-30.
71. Kunze, K. L., Eddy, A. C., Gibaldi, M., and Trager, W. F. (1991). Metabolic enantiomeric interactions: The inhibition of human (S) warfarin-7-hydroxylase by (R) warfarin. Chirality 3:24-29.
72. Laizure, S. C., De Vane, C. L., Stewart, J. T., Dommisse, C. S., and Lai, A. A. (1985). Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose. Clin. Pharmacol. Ther. 38:586-589.
73. Lavoie, P.-A., Beuachamp, G., and Elie, R. (1994). Absence of stereoselectivity of some tricyclic antidepressants for the inhibition of depolarization-induced calcium uptake in rat cingulate cortex synaptosomes. J. Psychiatr. Neurosci. 19:208
74. Lee, E. J. D., and Williams, K. M. (1990). Chirality: Clinical pharmacokinetic and pharmacodynamic considerations. Clin. Pharmacokinet. 18:339-345.
75. Lee, S. K-S., Baker, G. B., and Coutts, R. T. (1995) Simultaneous determination of the enantiomers of trimipramine by high pressure liquid chroamtography (HPLC): Application to rat tissue samples. Proc. 18th Annu. Meet. Can. Coll. Neuropsychopharmacol., Vancouver, BC.
76. Magyar, K., and Tothfalusi, L. (1984). Pharmacokinetic aspects of deprenyl effects. Pol. J. Pharmacol. Pharm. 36:373-384.
77. Magyar, K., Vizi, E. S., and Esceri, Z. (1967). Comparative pharmacological analysis of the optical isomers of phenyl-isopropyl-methylpropinylamine (E250). Acta Physiol. Hung. 32:377-387.
78. Maura, G., Gemignani, A., and Raiteri, M. (1985). Alpha 2-adrenoceptors in rat hypothalamus and cerebral cortex: Functional evidence for pharmacologically distinct subpopulations. Eur. J. Pharmacol. 116:335-339.
79. Medical Economics Data (1995). Luvox (fluvoxamine maleate). In Physicians Desk Reference, 49th ed., Medical Economics Data Production Co., Montvale, NJ, Suppl. A, pp. 44-47.
80. Mehvar, R., and Jamali, F. (1997). Bioequivalence of chiral drugs. Stereospecific versus non-stereospecific methods. Clin. Pharmacokinet. 33:122-141.
81. Mendlewicz, J. (1995). Pharmacologic profile and efficacy of venlafaxine. Int. Clin. Psychopharmacol. 2:5-13.
82. Midha, K. K., Hubbard, J. W., McKay, G., Hawes, E. M., Korchinski, E. D., Gurnsey, T., Cooper, J. K., and Schwede, R. (1992). Stereoselective pharmacokinetics of doxepin isomers. Eur. J. Clin. Pharmacol. 42:539-544.
83. Muller, W. E., and Wollert, U. (1975). High stereospecificity of the benzodiazepine binding site on human albumin. Studies with d- and l-oxazepam hemisuccinate. Mol. Pharmacol. 11:52-60.
84. Mutschler, E., Gietl, Y., Krauss, D., Martin, E., Pflugmann, G., and Weber, H. (1990). Stereospecific analysis and human pharmacokinetics of the enantiomers of drugs administered as racemates. In Holmstedt, B., Frank, H. and Testa, B. (eds.), Chirality and Biological Activity, Alan R. Liss, New York, pp. 199-219.
85. Nation, R. L. (1994). Chirality in new drug development: Clinical pharmacokinetic considerations. Clin. Pharmacokinet. 27:249-255.
86. Nerurkar, S. G., Dighe, S. V., and Williams, R. L. (1992). Bioequivalence of racemic drugs. J. Clin. Pharmcol. 32:935-943.
87. Nickolson, V. J., and Pinder, R. M. (1984). In Smith, D. F. (ed.), Handbook of Stereoisomers: Drugs in Psychopharmacology, CRC Press, Boca Raton, FL, pp. 215-240.
88. Nordin, C., and Bertilsson, L. (1995). Active hydroxymetabolites of antidepressants. Clin. Pharmacokinet. 28:26-40.
89. Nusser, E., Nill, K., and Breyer-Paff, U. (1988). Enantioselective formation and disposition of (E)- and (Z)-10-hydroxynortriptyline. Drug Metab. Dispos. 16:509-511.
90. Otton, S. V., Ball, S. E., Cheung, S. W., Inaba, T., Rudolph, R. L., and Sellers, E. M. (1996). Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br. J. Clin. Pharmacol. 41:149-156.
91. Peet, M., and Behagel, H. (1978). Mianserin: a decade of scientific development. Br. J. Clin. Pharmacol. 5:5S-9S.
92. Pichini, S., Pacifici, R., Altieri, I., Pellegrini, M., and Zuccaro, P. (1996). Stereoselective determination of fluoxetine and nofluoxetine enantiomers in plasma samples by high pressure liquid chromatography. J. Liq. Chromatogr. Rel. Technol. 19:1927-1935.
93. Pinder, R. M. (1985). Adrenoreceptor interactions of the enantiomers and metabolites of mianserin: Are they responsible for the antidepressant effect? Acta Psychiatr. Scand. Suppl. 320:1-9.
94. Pinder, R. M, and van Delft, A. M. (1983a). Pharmacological aspects of mianserin. Acta Psychiatr. Scand. Suppl. 302:59-71.
95. Pinder, R. M., and van Delft, A. M. L. (1983b). The potential therapeutic role of the enantiomers and metabolites of mianserin. Br. J. Clin. Pharmacol. 15:269S- 276S.
96. Pinder, R. M., Brogden, R. N., Speight, T. M., and Avery, G. S. (1977). Doxepin up-to-date: A review of its pharmacological properties and therapeutic efficacy with particular reference to depression. Drugs 13:161-218.
97. Posner, J., Bye, A., Dean, K., Peck, A. W., and Whiteman, P. D. (1985). The disposition of bupropion and its metabolites in healthy male volunteers after single and multiple doses. Eur. J. Clin. Pharmacol. 29:97-103.
98. Potts, B. D., and Parli, C. J. (1992). Analysis of the enantiomers of fluoxetine and norfluoxetine in plasma and tissue using chiral derivatization and normal-phase liquid chromotography. J. Liq. Chromatogr. 15:665-681.
99. Raiteri, M., Maura, G., and Versace, P. (1983). Functional evidence for two stereochemically different alpha-2 adrenoceptors regulating central norepinephrine and serotonin release. J. Pharmacol. Exp. Ther. 224:679-684.
100. Rauws, A. G., and Groen, K. (1994). Current regulatory (draft) guidance on chiral medicinal products: Canada, EEC, Japan, United States. Chirality 6:72-75.
101. Reynolds, G. P., Elsworth, J. D., Blau, K., Sandler, M., Lees, A. J., and Stern, G. M (1978). Deprenyl is metabolized to methylamphetamine and amphetamine in man. Br. J. Clin. Pharmacol. 6:542-544.
102. Reynolds, G. P., and Riederer, P. (1981). Tranylcypromine isomers in the treatment of Parkinson's disease: Biochemical effects. Int. Pharmacopsychiat 16:30-33.
103. Reynolds, J. E. F. (ed.) (1982). Martindale: The Extra Pharmacopeia, 28th ed., Pharmceutical Press, London, p 133.
104. Rochat, B., Amery, M., and Bauman, P. (1995). Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography. Ther. Drug. Monitor. 17:273-279.
105. Rosseel, M. T., Bogaert, M. G., and Claeys, M. (1978). Quantitative GLC determination of cis- and trans-isomers of doxepin and desmethyldoxepin. J. Pharm. Sci. 67:802-805.
106. Ruelius, H. W., Tio, C. O., Knowles, J. A., McHugh, S. L., Schilling, R. T., and Sisenwine, S. F. (1979). Diastereoisomeric glucuronides of oxazepam: Isolation and stereoselective enzymic hydrolysis. Drug Metab. Dispos. 7:40-43.
107. Salama, A., and Mueller-Eckhardt., C. (1985). The role of metabolite-specific antibodies in nomifensinedependent immune hemolytic anemia. N. Engl. J. Med. 313:469-474.
108. Schoemaker, H., Berendsen, H. H., Stevens, H. J., and Nickolson, V. J. (1981). Differences in presynaptic alpha-blockade, noradrenaline uptake inhibition, and potential antidepressant activity between (+)- and (-)mianserin. Psychopharmacology 74:137-142.
109. Schurig, V. (1994). Enantiomer separation by gas chromatography on chiral stationary phases. J. Chromatog. 666:111-129.
110. Settle, E. C., and Ayd, F. J. (1980). Trimipramine: Twenty years' worldwide clinical experience. J. Clin. Psychiat. 41:266-274.
111. Sidhu, J., Priskorn, M., Powlsen, M., Segonzac, A., Grollier, G., and Larsen, M. (1997). Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. Chirality 9:686-692.
112. Sisenwine, S. F., Tio, C. O., Hadley, F. V., Liu, A. L., Kimmmel, H. B., and Ruelius, H. W. (1982). Species-related differences in the stereoselective glucuronidation of oxazepam. Drug Metab. Dispos. 10:605-608.
113. Sjöqvist, F., Alenxanderson, B., Ashberg, M., Bertilsson, L., Borga, O., Hamberger, B., and Tuck, D. (1979). Pharmacokinetics and biological effects of nortriptyline in man. Acta Pharmacol. Toxicol. 29 (Suppl. 3):255-280.
114. Smith, D. F. (1984). CRC Handbook of Stereoisomers: Drugs in Psychopharmacology, CRC Press, Boca Raton, FL.
115. Spahn-Langguth, H., Hahn, G., Mutschler, E., Mohrke, W., and Langguth, P. (1992). Enantiospecific high-performance liquid chromatographic assay with fluorescence detection for the monoamine oxidase inhibitor tranylcypromine and its applicability in pharmacokinetic studies. J. Chromatogr. Biomed. Appl. 584:229-237.
116. Srinivas, N. R., Shyu, W. C., and Barbhaiya, R. H. (1995). Gas chromatographic determination of enantiomers as diastereomers following pre-column derivatization and applications to pharmacokinetic studies: A review. Biomed. Chromatogr. 9:1-9.
117. Stevens, J. C., and Wrighton, S. A. (1993). Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450. J. Pharmacol. Exp. Ther. 266:964-971.
118. Subert, J. (1994). Progress in the separation of enantiomers of chiral drugs by HPLC without their prior derivatization. Pharmazie 49:3-13.
119. 1 and D2 receptors in rat brain. Neuropharmacology 27:1117-1124.
120. Terabe, S., Otsuka, K., and Nishi, H. (1994). Separation of enantiomers by capillary electrophoretic techniques. J. Chromatogr. A 666:295-319.
121. Testa, B. (1986). Chiral aspects of drug metabolism. Trends Pharmacol. Sci. 7:60-64.
122. Torok-Both, G. A., Baker, G. B., Coutts, R. T., McKenna, K. F., and Aspeslet, L. J. (1992). Simultaneous determination of fluoxetine and norfluoxetine enantiomers in biological samples by gas chromatography with electroncapture detection. J. Chromatogr. 579:99-106.
123. Tucker, G. T., and Lennard, M. S. (1990). Enantiomer specific pharmacokinetics. Pharmacol. Ther. 45:309-329.
124. Tybring, G., Otani, K., Kaneko, S., Mihara, K., Fukushima, and Bertilsson, L. (1995). Enantioselective determination of mianserin and its desmethyl metabolite in plasma during treatment of depressed Japanese patients. Ther. Drug Monit. 17:516-521.
125. Van Harten, J. (1993). Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin. Pharmacokinet. 24:203-220.
126. Vespalec, R., and Bocek, P. (1994). Chiral state of the art. Electrophoresis 15:755-762
127. von Bahr, C., Movin, G., Nordin, C., Liden, A., Hammarlund-Udenaes, M., Hedberg, A., Ring, H., and Sjoqvist, F. (1991). Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin. Pharmacol. Ther. 49:234-239.
128. Weber-Grandke, H., Hahn, G., Mutschler, E., Möhrke, W., Langguth, P., and Spahn-Langguth, H. (1993). The pharmacokinetics of tranylcypromine enantiomers in healthy subjects after oral administration of racemic drug and the single enantiomers. Br. J. Clin. Pharmacol. 36:363-365.
129. Wong, D. T., Fuller, R. W., and Robertson, D. W. (1990). Fluoxetine and its two enantiomers as selective serotonin uptake inhibitors. Acta Pharma. Nordica 2:171-179.
130. Wong, D. T., Bymaster, F. P., Reid, L. R., Mayle, D. A., Krushinski, J. H., and Robertson D. W. (1993). Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brain. Neuropsychopharmacology 8:337-344.
131. Wong, D. T., Bymaster, F. P., and Engleman, E. A. (1995) Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: Twenty years since its first publication. Life Sci. 57:411-441.
132. 3 receptors. J. Pharm. Pharmacol. 45:711-714.
133. Yang, S. K., and Lu, X. L. (1989). Racemization kinetics of enantionmeric oxazepams and stereoselective hydrolysis of enantiomeric oxazepam 3-acetates in rat liver microsomes and brain homogenate. J. Pharm. Sci. 78:789-795.
134. Yang, S. K., and Lu X.-L. (1992). Resolution and stability of oxazepam enantiomers. Chirality 4:443-446.